Campbell & CO Investment Adviser LLC Purchases New Holdings in Axon Enterprise, Inc $AXON

Campbell & CO Investment Adviser LLC acquired a new position in Axon Enterprise, Inc (NASDAQ:AXON) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 3,345 shares of the biotechnology company’s stock, valued at approximately $2,769,000.

Several other large investors also recently bought and sold shares of the company. Brighton Jones LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter worth approximately $480,000. Fidelis Capital Partners LLC lifted its holdings in Axon Enterprise by 15.9% in the 1st quarter. Fidelis Capital Partners LLC now owns 619 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 85 shares in the last quarter. Arizona State Retirement System boosted its stake in Axon Enterprise by 0.5% during the 1st quarter. Arizona State Retirement System now owns 20,927 shares of the biotechnology company’s stock worth $11,007,000 after purchasing an additional 107 shares during the last quarter. CWM LLC grew its holdings in shares of Axon Enterprise by 3.2% during the first quarter. CWM LLC now owns 4,713 shares of the biotechnology company’s stock worth $2,479,000 after buying an additional 147 shares in the last quarter. Finally, Prudent Man Advisors LLC raised its position in shares of Axon Enterprise by 1.6% in the first quarter. Prudent Man Advisors LLC now owns 1,298 shares of the biotechnology company’s stock valued at $683,000 after buying an additional 20 shares during the last quarter. 79.08% of the stock is currently owned by hedge funds and other institutional investors.

Axon Enterprise Stock Up 2.6%

Shares of NASDAQ AXON opened at $602.51 on Monday. The company has a market capitalization of $47.54 billion, a P/E ratio of 148.77, a P/E/G ratio of 29.49 and a beta of 1.45. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. The company has a 50 day simple moving average of $719.61 and a 200-day simple moving average of $737.16. Axon Enterprise, Inc has a 1 year low of $469.24 and a 1 year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The business had revenue of $710.64 million during the quarter, compared to analyst estimates of $704.83 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company’s revenue was up 30.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.45 earnings per share. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, Director Hadi Partovi acquired 1,358 shares of the business’s stock in a transaction that occurred on Wednesday, August 13th. The stock was purchased at an average cost of $740.00 per share, with a total value of $1,004,920.00. Following the transaction, the director owned 237,938 shares of the company’s stock, valued at $176,074,120. This trade represents a 0.57% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Patrick W. Smith sold 10,000 shares of the business’s stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $713.74, for a total transaction of $7,137,400.00. Following the completion of the sale, the chief executive officer owned 3,033,982 shares in the company, valued at approximately $2,165,474,312.68. This trade represents a 0.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 49,932 shares of company stock worth $36,802,716. Insiders own 4.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AXON. Raymond James Financial restated an “outperform” rating and set a $855.00 price target (up from $645.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Zacks Research lowered shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 2nd. Northland Securities set a $800.00 target price on Axon Enterprise in a report on Tuesday, August 5th. JPMorgan Chase & Co. increased their price target on Axon Enterprise from $730.00 to $850.00 and gave the company an “overweight” rating in a report on Thursday, July 17th. Finally, UBS Group reduced their price objective on Axon Enterprise from $840.00 to $610.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Fifteen equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and a consensus price target of $810.71.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.